Skip to main content
SpringerLink
Log in

Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Two trials have been performed in the same patients with hyperlipoproteinaemia Types IIb (12 cases), III (6 cases) and IV (11 cases). In the first study the lipid-lowering properties of bezafibrate, fenofibrate, gemfibrozil, etofibrate and etofylline clofibrate were compared and in a separate trial the influence of combined treatment with gemfibrozil plus colestipol and bezafibrate plus probucol on lipoproteins were investigated. The mean percentage lipid-lowering effect of each fibrate on serum and VLDL fraction was significant in the Types IIb, III and IV patients, but there were significant differences between the fibrates. In general, gemfibrozil and bezafibrate decreased plasma lipid levels more than etofibrate and etofylline clofibrate in Type IIb patients. In Type IV cases gemfibrozil and bezafibrate were significantly potent in reducing the triglyceride level than fenofibrate, etofibrate or etofylline clofibrate. All the fibrates produced an increase in HDL cholesterol, but there were significant differences between them were in the Type IV patients. The influence of fibrates on the LDL fraction was much more variable. In hyperlipoproteinaemia Type IIb, a decrease in both LDL cholesterol and LDL apolipoprotein B was observed. In Type III and IV patients, however, an increase in LDL concentration occurred. The addition of colestipol to gemfibrozil therapy led to a further decrease in total cholesterol, LDL cholesterol and LDL apolipoprotein B in Type IIb patients. In patients with hyperlipoproteinaemia Types III and IV colestipol prevented the increase in LDL concentration after treatment with gemfibrozil alone. The effect of probucol on LDL cholesterol was comparable to that of colestipol. Combined treatment with gemfibrozil and colestipol caused an increase in HDL cholesterol concentration in contrast to combined treatment with bezafibrate and probucol. It is concluded that combined therapy with fibrates plus bile acid sequestrant would be of practical value in patients with hyperlipoproteinaemia Types IIb, III and IV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Blane GF (1987) Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. Am J Med 83 [Suppl 5B]: 26–36

    Google Scholar 

  2. Grundy SM, Vega GL (1987) Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med 83 [Suppl 5B]: 9–20

    Google Scholar 

  3. Hunninghake DB, Peters JR (1987) Effect of fibric acid derivatives on blood lipid and lipoprotein levels. Am J Med 83 [Suppl 5B]: 44–49

    Google Scholar 

  4. Illingworth DR (1987) Lipid lowering drugs. An overview of indications and optimum therapeutic use. Drugs 33: 259–279

    Google Scholar 

  5. Monk JP, Todd PA (1987) Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs 33: 539–576

    Google Scholar 

  6. Shepherd J, Packard CJ (1986) An overview of the effects of p-chlorophenoxyisobutyric acid derivatives on lipoprotein metabolism. In: Pharmacological Control of Hyperlipidaemia. (ed) JR Prous Science Publishers SA, pp 135–144

  7. Todd PA, Ward A (1988) Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia. Drugs 36: 314–339

    Google Scholar 

  8. East C, Bilheimer DW, Grundy SM (1988) Combination drug therapy for familial combined hyperlipidemia. Ann Int Med 109: 25–32

    Google Scholar 

  9. Carlson LA, Olsson AG, Ballantyne D (1977) On the rise in low density and high density lipoproteins in response to the treatment of hypertriglyceridaemia in type IV and V hyperlipoproteinaemias. Atherosclerosis 26: 603–609

    Google Scholar 

  10. Eisenberg S, Gavish D, Oschry Y, Fainaru M, Deckelbaum RJ (1984) Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. J Clin Invest 74: 470–482

    Google Scholar 

  11. Grundy SM (1988) Lessons from the Helsinki Heart Study. Fibric acid therapy for dyslipidemia. Postgrad Med 84: 217–231

    Google Scholar 

  12. Kłosiewicz-Latoszek L, Nowicka G, Szostak WB, Naruszewicz M (1987) Influence of bezafibrate and colestipol on LDL cholesterol, LDL apolipoprotein B and HDL cholesterol in hyperlipoproteinemia. Atherosclerosis 63: 203–209

    Google Scholar 

  13. Naruszewicz M, Szostak WB, Cybulska B, Chotkowska E, Kozłowska M (1980) The influence of clofibrate on lipid and protein components of very low density lipoprotein in Type IV hyperlipoproteinemia. Atherosclerosis 35: 383–392

    Google Scholar 

  14. Naruszewicz M, Szostak WB, Kłosiewicz-Latoszek L, Nowicka G, Cybulska B (1983) Effect of bezafibrate on serum lipids and lipoproteins in hyperlipoproteinaemia. Żyw Człow Metab 10: 52–57

    Google Scholar 

  15. Sommariva D, Bonfiglioli D, Pogliaghi I, Ottomano C, Fasoli A (1984) Fenofibrate therapy of hypertriglyceridaemias. Differential effects on LDL cholesterol level in type IV and type IIb primary hyperlipoproteinaemia. Eur J Clin Pharmacol 26: 741–744

    Google Scholar 

  16. Weisweiler P, Schwandt P (1982) Effect of bezafibrate on apolipoproteins in Type IV hyperlipoproteinemia cases. In: Crepaldi G, Greten H, Schettler G, Baggio G (eds), Lipoprotein metabolism and therapy of lipid disorders. Excerpta Medica, Amsterdam Oxford Princeton, pp 170–172

    Google Scholar 

  17. Paoletti R, Franceschini G, Sirtori CR (1983) Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels. Am J Cardiol 52: 218–278

    Google Scholar 

  18. Thompson GR (1989) Drug treatment of hyperlipidemia. In: Thompson GR (ed) A handbook of hyperlipidaemia. Current Science Ltd, London, pp 177–194

    Google Scholar 

  19. Rabin SW, Hayden M, Frohlich J (1988) Comparison of gemfibrozil and clofibrate on serum lipids in familial combined hyperlipidemia. A randomized placebo-controlled, double-blind, crossover clinical trial. Atherosclerosis 73: 233–240

    Google Scholar 

  20. Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS, Strasser T (1980) WHO classification of hyperlipidaemias and hyperlipoproteinaemias. WHO Bull 43: 891–899

    Google Scholar 

  21. Carlson K (1973) Lipoprotein fractionation. J Clin Pathol 26 [Suppl 5]: 32–37

    Google Scholar 

  22. Utermann G, Kindermann I, Kaffarnik H, Steinmetz A (1984) Apolipoprotein E phenotypes and hyperlipidemia. Hum Genet 65: 232–236

    Google Scholar 

  23. Warnick GR, Mayfield G, Albers JJ, Hazzard WR (1979) Gel isoelectric focusing method for specific diagnosis of familial hyperlipoproteinemia Type III. Clin Chem 25: 279–285

    Google Scholar 

  24. Nowicka G (1983) Serum apolipoprotein B determination by radial immunodiffusion (RID) in clinical practice. Żyw Człow Metab 10: 59–67

    Google Scholar 

  25. Vega GL, Grundy SM (1985) Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. Effects on metabolism of low-density lipoproteins. JAMA 253: 2398–2403

    Google Scholar 

  26. Eisenberg S (1987) Lipoprotein abnormalities in hypertriglyceridemia: significance in atherosclerosis. Am Heart J 113: 555–561

    Google Scholar 

  27. Eisenberg G, Gavish D, Kleinman Y (1986) Bezafibrate. In: Pharmacological control of hyperlipidaemia (ed) J R Prous Science Publishers SA, pp 145–169

  28. Kesaniemi YA, Grundy SM (1984) Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglyceride in man. JAMA 251: 2241–2246

    Google Scholar 

  29. Nash DT (1982) Clinical investigation of gemfibrozil: gemfibrozil versus clofibrate. Cardiovasc Rev Rep 3: 1207–1214

    Google Scholar 

  30. Ginsberg HN (1987) Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives. Am J Med 83 [Suppl 58]: 66–70

    Google Scholar 

  31. Ducobu J, Dupont P (1986) Use of bezafibrate in fenofibrate-resistant hypertriglyceridemic patients. Curr Ther Res 39: 126–130

    Google Scholar 

  32. Tesone PA, Gladstein J, Acuna AM (1985) Comparative study of bezafibrate and fenofibrate in patients with primary hyperlipoproteinaemia. Curr Med Res Opin 9: 650–657

    Google Scholar 

  33. National Heart, Lung and Blood Institute. Report of the National Cholesterol Education Program: Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol Levels in Adults (1988) Arch Intern Med 148: 36–69

  34. Stewart JM, Packard CJ, Lorimer AR, Boag DE, Shepherd J (1982) Effects of bezafibrate on receptor-mediated and receptor independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects. Atherosclerosis 44: 355–365

    Google Scholar 

  35. Knopp RH, Brown WV, Dujovne CA, Farquhar JW, Feldman EB, Goldberg AC, Grundy SM, Lasser NL, Mellies MJ, Palmer RH, Samuel P, Schonfeld G, Superko HR (1987) Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. Am J Med 83 [Suppl 58]: 50–59

    Google Scholar 

  36. Hoogwerf BJ, Peters JR, Frantz ID, Hunninghake DB (1985) Effect of clofibrate and colestipol singly and in combination on plasma lipids and lipoproteins in type III hyperlipoproteinemia. Metabolism 34: 978–981

    Google Scholar 

  37. Goldberg AC, Schonfeld G, Anderson C, Dillingham MA (1987) Fenofibrate affects the compositions of lipoproteins. Am J Med 83 [Suppl 58]: 60–65

    Google Scholar 

  38. Lewis JE (1983) Multicenter Collaborative Study Group. Clinical use of gemfibrozil: a controlled multicenter trial. Pract Cardiol 9: 99–118

    Google Scholar 

  39. Gavish D, Oschry Y, Fainaru M, Eisenberg S (1986) Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIa and type IIb hyperlipoproteinaemia. Eur J Clin Invest 16: 61–68

    Google Scholar 

  40. Rudel LL, Parks JS, Johnson FL, Babiak J (1986) Low density lipoproteins in atherosclerosis. J Lip Res 27: 465–474

    Google Scholar 

  41. Shepherd J, Caslake MJ, Lorimer AR, Vallance RD, Packard CJ (1985) Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects. Arteriosclerosis 5: 162–168

    Google Scholar 

  42. Vega GL, Grundy SM (1989) Studies on mechanisms for enhanced clearance of low density lipoproteins in patients with primary hypertriglyceridaemia. J Intern Med 226: 5–15

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Nutrition, National Food and Nutrition Institute, Warsaw, Poland

    L. Kłosiewicz-Latoszek & W. B. Szostak

Authors
  1. L. Kłosiewicz-Latoszek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. B. Szostak
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kłosiewicz-Latoszek, L., Szostak, W.B. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia. Eur J Clin Pharmacol 40, 33–41 (1991). https://doi.org/10.1007/BF00315136

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00315136

Key words

Search

Navigation